Halozyme elects James Daly to board, term runs through 2029 annual meeting

HALOZYME THERAPEUTICS, INC.

James Daly was elected to Halozyme Therapeutics' Board of Directors on September 28, 2026.
Daly's director term ends at the company's annual meeting of stockholders in 2029; he was not assigned to any board committee.
Daly will receive compensation under Halozyme's non-employee director program, including cash retainers and restricted stock and stock option awards.
Halozyme said there are no arrangements or understandings for Daly's election and no related person transactions between him and the company.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.